Results 201 to 210 of about 45,883 (301)

When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology

open access: yesCytopathology, EarlyView.
Small cell carcinoma of the bladder is rare, aggressive and diagnostically challenging on urine cytology. We report a case detected in urine and confirmed by cell block immunohistochemistry, highlighting the importance of careful assessment and limitations of the Paris System.
Haley Corbin   +3 more
wiley   +1 more source

Right medial temporal lobe mass in a 25‐year‐old male

open access: yes
Brain Pathology, EarlyView.
Jorge Samanamud   +10 more
wiley   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta   +14 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy